Boosting the body’s ability
to fight cancer by designing
next generation oncolytic
immunotherapies

Science

Our patented TILT® technology, based on oncolytic viral therapies, modifies the tumour microenvironment and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T therapies.

Learn more

Pipeline

We have multiple best-in-class oncolytic viral therapies. In our pipeline, our lead therapeutic asset, TILT-123, is a cytokine armed oncolytic adenovirus that is currently in Phase 1 clinical trials as monotherapy and in combination with tumor infiltrating lymphocytes (TIL) therapy in Europe.

View pipeline

Partners

Our pioneering approach has been recognized by industry leaders including Germany’s Merck KGaA and MSD (a tradename of Merck & Co., Inc.).

Learn more